US FDA Biosimilars Acting Director Yim ‘Not A Great Fan’ Of Suffix-Based Naming Policy

 
• By Sue Sutter
  
question-mark-tiles_762800164
Biosimilars program acting director Sarah Yim said she questioned the need for distinguishable, nonproprietary names for biosimilars.

More from Biosimilars

More from Biosimilars & Generics